MA39040A1 - Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) - Google Patents
Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)Info
- Publication number
- MA39040A1 MA39040A1 MA39040A MA39040A MA39040A1 MA 39040 A1 MA39040 A1 MA 39040A1 MA 39040 A MA39040 A MA 39040A MA 39040 A MA39040 A MA 39040A MA 39040 A1 MA39040 A1 MA 39040A1
- Authority
- MA
- Morocco
- Prior art keywords
- aml
- combination therapy
- myeloid leukemia
- acute myeloid
- new combination
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention concerne un produit pharmaceutique qui comprend : a) en tant que premier composant, un inhibiteur de l'interaction mdm2-p53 ; et b) en tant que second composant, de la cytarabine ; sous forme de préparation combinée pour l'utilisation simultanée ou séquentielle dans le traitement du cancer, en particulier de la lam.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912152P | 2013-12-05 | 2013-12-05 | |
| PCT/EP2014/076063 WO2015082384A1 (fr) | 2013-12-05 | 2014-12-01 | Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39040A1 true MA39040A1 (fr) | 2018-01-31 |
Family
ID=52014047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39040A MA39040A1 (fr) | 2013-12-05 | 2016-05-17 | Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20160303158A1 (fr) |
| EP (1) | EP3077004B1 (fr) |
| JP (3) | JP6297695B2 (fr) |
| KR (1) | KR101862955B1 (fr) |
| CN (1) | CN105792847B (fr) |
| AR (1) | AR098576A1 (fr) |
| AU (1) | AU2014359422B2 (fr) |
| BR (1) | BR112016009669B1 (fr) |
| CA (1) | CA2926307C (fr) |
| CL (1) | CL2016001345A1 (fr) |
| CR (1) | CR20160173A (fr) |
| DK (1) | DK3077004T3 (fr) |
| EA (1) | EA201690785A1 (fr) |
| ES (1) | ES2785203T3 (fr) |
| HR (1) | HRP20200566T1 (fr) |
| HU (1) | HUE049434T2 (fr) |
| IL (1) | IL244888B (fr) |
| LT (1) | LT3077004T (fr) |
| MA (1) | MA39040A1 (fr) |
| MX (1) | MX370618B (fr) |
| PE (1) | PE20160591A1 (fr) |
| PH (1) | PH12016500933A1 (fr) |
| PL (1) | PL3077004T3 (fr) |
| PT (1) | PT3077004T (fr) |
| RS (1) | RS60142B1 (fr) |
| SG (1) | SG11201604504VA (fr) |
| SI (1) | SI3077004T1 (fr) |
| TW (2) | TWI678204B (fr) |
| WO (1) | WO2015082384A1 (fr) |
| ZA (1) | ZA201602829B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508531B1 (fr) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Polypeptides piqués |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| WO2014071241A1 (fr) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci |
| EP3077004B1 (fr) * | 2013-12-05 | 2020-02-19 | F.Hoffmann-La Roche Ag | Nouvelle thérapie combinatoire pour le treatment de la leucémie myéloïde aiguë (aml) |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| WO2016154058A1 (fr) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leurs utilisations |
| AU2016315878A1 (en) * | 2015-09-03 | 2018-03-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| SG11201809501PA (en) * | 2016-06-06 | 2018-12-28 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| WO2018027477A1 (fr) * | 2016-08-08 | 2018-02-15 | 肖飞 | Composé de carbonate de polyéthylène glycol d'indolone spirocyclique, composition, procédé de préparation et utilisation de ceux-ci |
| PL3541387T3 (pl) | 2016-11-15 | 2021-10-25 | Novartis Ag | Dawka i schemat dla inhibitorów interakcji hdm2-p53 |
| KR20190129889A (ko) * | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3858361B1 (fr) | 2018-09-28 | 2025-10-08 | FUJIFILM Corporation | Agent antitumoral contenant de la cytarabine, activateur d'effet antitumoral utilisé en combinaison avec la cytarabine, kit antitumoral, et agent antitumoral utilisé en combinaison avec le cytarabine |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| TW202118488A (zh) * | 2019-07-26 | 2021-05-16 | 大陸商蘇州亞盛藥業有限公司 | Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途 |
| CA3218640A1 (fr) * | 2021-05-13 | 2022-11-17 | Kanya Lakshmi RAJANGAM | Schemas posologiques pour l'immunotherapie anticancereuse |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125888B2 (en) * | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE102005012681A1 (de) * | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CN101773408B (zh) * | 2010-01-15 | 2012-04-04 | 平荧 | 多功能排针结合电凝固技术提升下垂皮肤的装置 |
| AU2011237782A1 (en) * | 2010-04-09 | 2012-10-25 | The Regents Of The University Of Michigan | Biomarkers for MDM2 inhibitors for use in treating disease |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| EP3077004B1 (fr) * | 2013-12-05 | 2020-02-19 | F.Hoffmann-La Roche Ag | Nouvelle thérapie combinatoire pour le treatment de la leucémie myéloïde aiguë (aml) |
| US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
-
2014
- 2014-12-01 EP EP14808911.3A patent/EP3077004B1/fr active Active
- 2014-12-01 JP JP2016536634A patent/JP6297695B2/ja active Active
- 2014-12-01 EA EA201690785A patent/EA201690785A1/ru unknown
- 2014-12-01 LT LTEP14808911.3T patent/LT3077004T/lt unknown
- 2014-12-01 AR ARP140104469A patent/AR098576A1/es unknown
- 2014-12-01 KR KR1020167014756A patent/KR101862955B1/ko active Active
- 2014-12-01 PT PT148089113T patent/PT3077004T/pt unknown
- 2014-12-01 BR BR112016009669-0A patent/BR112016009669B1/pt active IP Right Grant
- 2014-12-01 CA CA2926307A patent/CA2926307C/fr active Active
- 2014-12-01 WO PCT/EP2014/076063 patent/WO2015082384A1/fr not_active Ceased
- 2014-12-01 HR HRP20200566TT patent/HRP20200566T1/hr unknown
- 2014-12-01 PE PE2016000615A patent/PE20160591A1/es not_active Application Discontinuation
- 2014-12-01 MX MX2016007170A patent/MX370618B/es active IP Right Grant
- 2014-12-01 SG SG11201604504VA patent/SG11201604504VA/en unknown
- 2014-12-01 US US15/101,258 patent/US20160303158A1/en not_active Abandoned
- 2014-12-01 ES ES14808911T patent/ES2785203T3/es active Active
- 2014-12-01 DK DK14808911.3T patent/DK3077004T3/da active
- 2014-12-01 HU HUE14808911A patent/HUE049434T2/hu unknown
- 2014-12-01 PL PL14808911T patent/PL3077004T3/pl unknown
- 2014-12-01 RS RS20200394A patent/RS60142B1/sr unknown
- 2014-12-01 SI SI201431551T patent/SI3077004T1/sl unknown
- 2014-12-01 AU AU2014359422A patent/AU2014359422B2/en active Active
- 2014-12-01 CN CN201480066531.9A patent/CN105792847B/zh active Active
- 2014-12-03 TW TW107105068A patent/TWI678204B/zh active
- 2014-12-03 TW TW103142020A patent/TWI627954B/zh active
- 2014-12-04 US US14/560,086 patent/US9956243B2/en active Active
-
2016
- 2016-04-04 IL IL244888A patent/IL244888B/en active IP Right Grant
- 2016-04-14 CR CR20160173A patent/CR20160173A/es unknown
- 2016-04-25 ZA ZA2016/02829A patent/ZA201602829B/en unknown
- 2016-05-17 MA MA39040A patent/MA39040A1/fr unknown
- 2016-05-19 PH PH12016500933A patent/PH12016500933A1/en unknown
- 2016-06-02 CL CL2016001345A patent/CL2016001345A1/es unknown
-
2018
- 2018-02-21 JP JP2018028482A patent/JP6918724B2/ja active Active
-
2020
- 2020-02-19 US US16/794,991 patent/US20200253999A1/en not_active Abandoned
-
2021
- 2021-02-05 JP JP2021017415A patent/JP2021091690A/ja active Pending
- 2021-05-19 US US17/324,248 patent/US20220031726A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/130,016 patent/US20230381215A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
| EP4219563A3 (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| PH12016500933A1 (en) | Novel combination treatment for acute myeloid leukemia (aml) | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
| MA40769A (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX2020007731A (es) | Compuestos moduladores de receptor de estrogeno. | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA35638B1 (fr) | 2-thiopyrimidinones | |
| CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| MA44079B1 (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
| WO2020055906A8 (fr) | Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k) | |
| MA32224B1 (fr) | Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales | |
| EP3650029A4 (fr) | Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
| MA40937A (fr) | Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation | |
| EP3991727A4 (fr) | Composition pour le traitement de maladies dégénératives du cerveau, contenant du 2-pentylfurane en tant que principe actif |